Jury 2013

  
  
Peter Courtland Agre, M.D. A native Minnesotan, Peter Agre studied chemistry at Augsburg College (B.A. 1970) and medicine at Johns Hopkins (M.D. 1974). Following Internal Medicine Residency at Case Western Reserve University Hospitals of Cleveland and Hematology-Oncology Fellowship at the University of North Carolina at Chapel Hill, Agre joined the faculty at the Johns Hopkins School of Medicine where his laboratory became widely recognized for discovering the aquaporins, a family of water channel proteins found throughout nature and responsible for numerous physiological processes as well as multiple clinical disorders. Following a term as Vice Chancellor at Duke Medical Center, Agre joined the Johns Hopkins Bloomberg School of Public Health in 2008, where he is University Professor and Director of the Malaria Research Institute and Program Director of the NIH International Center of Excellence in Malaria Research for Zambia and Zimbabwe.
Agre shared the 2003 Nobel Prize in Chemistry with Roderick MacKinnon “for discoveries concerning channels in cell membranes.” Agre has received additional honors including the Distinguished Eagle Scout Award from the Boy Scouts of America. Agre is a member of the National Academy of Sciences and the Institute of Medicine; he is past-Chair and member of the Committee on Human Rights of the National Academies.
From 2009-11, Agre served as President and Chair of the Board of Directors of the American Association for the Advancement of Sciences and led scientific diplomacy visits to Cuba, Democratic Republic of Korea (North Korea), and Myanmar (Burma). Agre and his wife Mary, a teacher, have been married 36 years and have four grown children.
Dr Agre is currently an University Professor and the Gilman Scholar Director at Johns Hopkins Malaria Research Institute, Bloomberg School of Public Health.

Elizabeth Blackburn, Ph.D. is the recipient of the 2009 Nobel Prize in Physiology or Medicine for her discoveries in telomere biology that have uncovered a new understanding of normal cell functioning and given rise to a growing field of inquiry.
Throughout her distinguished career, Dr. Elizabeth Blackburn has spent countless hours in service to her constituency. Further, she has held leadership positions in several scientific societies, including her current appointment as President of the American Association for Cancer Research. 
Dr. Blackburn has been recognized for her contribution to the field of telomere biology with numerous prizes, awards, and honorary degrees, including the 2006 Albert Lasker Award for Basic Medical Research and elections to the American Association for the Advancement of Science and the Institute of Medicine. In 2007, Time magazine named her one of the ‘100 Most Influential People in the World,’ and in 2008 she was the North American Laureate for the L’Oreal_UNESCO For Women In Science. The scientific community bestowed upon her the ultimate recognition of her legacy by honoring Dr. Elizabeth Blackburn with the 2009 Nobel Prize in Physiology or Medicine.
 
Dr. Blackburn is currently the Morris Herzstein Endowed Chair in Biology and Physiology in the Department of Biochemistry and Biophysics at the University of California, San Francisco. She is also a Non-Resident Fellow of the Salk Institute.
Alice Dautry, is President of the Institut Pasteur. She was trained as a physicist at the University of Paris and as a molecular biologist at the University of New York.
 
She has devoted her career in France and during her stays in the United States, at the National Institutes of Health and the Massachusetts Institute of Technology, to research, training, teaching and evaluation and management of research. Prof. Alice Dautry has published some 130 publications in international scientific journals dealing with her studies in cell biology, receptors and infectious agents. Her teaching activities included: Professor at Ecole Polytechnique, Director of the Molecular Biology of the Cell course at the Institut Pasteur, training of PhD students and post doctoral fellows.
She is a member of the Board of trustees of higher education and research institutions, and international organisations, Ecole Polytechnique, Institute of Science and Technology Austria (Austria), Drugs for Neglected Diseases Initiative (Switzerland), Chr Hansen (Denmark), of the External Reference Group for Health Research Strategy of the WHO and Instituts Pasteur in the world.

Professor Ivan Dedov is the president of the Russian Academy of Medical Sciences and a member of the Russian Academy of Sciences.
He graduated from the Voronezh Medical Institute in 1964 and devoted much time to fundamental and applied problems of endocrinology, especially study of the neuro-endocrine system in phylogenesis, genomic and postgenomic technologies, proteomicmarkers of endocrine system disease pathogenesis. Ivan Dedov obtained the professor rank in 1987 and held leadership positions in scientific societies. He conducted pioneer research in development of gene and cell technologies for the treatment of hormone active tumors of endocrine glands, diseases of the hypothalamic-hypophysial and reproductive systems, hereditary endocrinopathies in children, problems of male female reproductive health as well as carrying out pharmaco-economic research.
Professor Ivan I. Dedov is one of eminent organizers in medical science in Russia, initiated creation of educational centers in leading institutions of the Russian Academy of Medical Sciences, organizer of Department of Pediatric Endocrinology with the post-graduate course of diabetology and endocrinology. In the capacity of the chief endocrinologist for the Russian Ministry of Health, I. I. Dedov upgraded endocrinological and diabetological services in Russia. He is a Coordinator of Diabetes mellitus Federal target program and the WHO expert in diabetes mellitus. Since 1990 and till present I. Dedov is a Director of Endocrinological Research Center and Federal Diabetological Centre, Ministry of Health.
Professor I. Dedov was awarded with the Order of Friendship and Orders of Honour 2nd, 3d and 4th classes.

Jörg Hinrich Hacker is the President of the German Academy of Sciences Leopoldina.
Prof. Hacker studied biology at the Martin Luther University in Halle and obtained his PhD in 1979. In 1988 he became professor of microbiology at the University of Würzburg and in 1993 Head of the Institute for Molecular Infection Biology in Würzburg. From 2008 to 2010, he was President of the Robert Koch Institute. His main research interests are the molecular analysis of bacterial pathogens, their spread and variability, as well as their interactions with host cells. From 2001 to 2008 he served as co-coordinator of programs for genomic research on bacterial pathogens, PathoGenoMik and PathoGenoMik Plus, for the Germay Federal Ministry of Education and Research.
Since March, 2010, Prof. Hacker has been President of the German Academy of Sciences Leopoldina. He is also editor-in-chief of the International Journal of Medical Microbiology. Among diverse awards and honors, he is a recipient of the Order of Merit of the Federal Republic of Germany.

Philippe Monteyne, MD, Ph.D. joined Sanofi on the 1st Oct 2012 as Vice President R&D France. He is therefore working at setting up a new Hub structure in France, across all R&D disciplines and all French sites, an organization of more than 6,000 scientists.

 

Philippe holds an M.D, a Ph.D. in Viral Immunology, and a Board Certification in Neurology. After an education in Belgium and France, and a position at Pasteur Institute in Paris, he joined SmithKline Beecham Biologicals in 1998 as a Medical Coordinator.
 

He was rapidly promoted Director, Head of the Program for Chronic Disorder Vaccines and Human Cellular Immunology Platform. In 2003 he took the position of VP, Worldwide Regulatory, Epidemiology and Safety for GSK (GlaxoSmithKline) Vaccines and then became VP, Worldwide Operations, Cervarix TM, and Head of Global Vaccine Development as of 2006. He moved to his most recent position at GSK in 2010, as Senior VP, Head of Development and Chief Medical Officer, GSK Rare Diseases.

 

Philippe is also a visiting Professor of Neurosciences at UCL in Belgium.


Philippe Sansonetti is Distinguished Professor at the Institut Pasteur where he directs the Molecular
Microbial Pathogenesis Unit and INSERM Unit 786.
 
Prof. Sansonetti received his M.D. degree in 1979 from the University Pierre et Marie Curie – Paris 6 and then did postdoctoral research in the Department of Enteric Infections at the Walter Reed Army Institute of Research in the United States. Returning to France, he began work at the Institut Pasteur, becoming Professor in 1994. In 2000 he also became an International Research Scholar of the Howard Hughes Medical Institute and since 2008 holds the Chair of Microbiology and Infectious Diseases at the Collège de France. His research concerns the molecular and genetic bases of bacterial pathogenesis as well as the molecular mechanisms of gut homeostasis and pathology in the presence of bacteria. With his team he has also developed the first candidate live attenuated vaccine against shigellosis, currently in clinical trials.
 
Prof. Sansonetti is a member of the French Academy of Sciences and a foreign member of the German Academy of Sciences Leopoldina and of the US National Academy of Sciences. He is a Chevalier de la Légion d'Honneur and a Commandeur de l'Ordre National du Mérite. Among many other awards, he received the Louis-Jeantet Prize of Medicine, the Robert Koch Prize in 1997 and the Grand Prix de l’INSERM in 2012.
 

Elias Zerhouni,
M.D., is the President, Global Research & Development, and a member of the Executive Committee for Sanofi. This new position brings R&D medicines and vaccines under one umbrella, enabling Sanofi to maximize opportunities for sharing and partnering the extensive wealth of experience and expertise that exists within the company, across Global Operations and the Vaccines Division.
Prior to becoming the President for Global Research & Development at Sanofi, Dr. Zerhouni served as a Scientific Advisor to the company and played an instrumental role in redesigning the Sanofi R&D model to foster increased innovation through scientific networks and exchange, creativity and flexibility.
Dr. Zerhouni’s academic career was spent at the renowned Johns Hopkins University and Hospital where he was professor of Radiology and Biomedical engineering and senior adviser for Johns Hopkins Medicine. He served as Chair of the Russell H. Morgan Department of Radiology and Radiological Sciences, Vice Dean for Research and Executive Vice Dean of the School of Medicine from 1996 to 2002 before his appointment as Director of the National Institutes of Health from 2002 to 2008. In that position he oversaw the NIH’s 27 Institutes and Centers with more than 18,000 employees and a budget of $29.5 billion (2008).
In November, 2009, President Obama appointed Dr. Zerhouni as one of the first presidential U.S. science envoys.
Dr. Zerhouni has founded or co-founded five start-up companies, authored more than 200 publications and holds eight patents and a number of prominent positions on several Boards, including most recently, Senior Fellow of the Bill and Melinda Gates Foundations, the board of trustees of the Mayo Clinic and the Lasker Foundation. He is also a member of the Institute of Medicine of the U.S. National Academy of Sciences, received the prestigious Legion of Honor medal from the French National Order in 2008, and was recently appointed as Chair of Innovation at the College de France and elected as a member of the French Academy of Medicine.